Full Press Release Details
argenx receives feedback from FDA in end-of-phase 2 meeting for efgartigimod in myasthenia gravis.
ARGX
argenx receives feedback from FDA in end-of-phase 2 meeting for efgartigimod in myasthenia gravis
Key Takeaway: argenx receives feedback from FDA in end-of-phase 2 meeting for efgartigimod in myasthenia gravis